The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
News|Videos|September 19, 2025
Intracranial Efficacy of Datopotamab Deruxtecan (DatoDXd) in Patients With Advanced/Metastatic NSCLC in TROPION-Lung01
Author(s)Jacob Sands, MD
Jacob Sands, MD, provides a post hoc analysis of TROPION-Lung01 , which showed improved intracranial activity and progression-free survival with datopotamab deruxtecan (Dato-DXd) versus docetaxel. Among patients with measurable brain metastases, Dato-DXd achieved a central nervous system confirmed overall response rate of 38%, with all evaluable patients showing disease control. No intracranial responses were seen in the docetaxel arm.
Advertisement
Advertisement
Related to this article
The 2026 amendment adds 40 new recommendations, including active surveillance, office-based treatment, and chemoablation for select recurrent low-grade disease.
The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.
By finding a way to attack the most important human oncogene, KRAS, the UCSF chemical biologist launched a new era in cancer treatment.
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Aglatimagene besadenovec plus EBRT was linked to a 41% lower risk of prostate cancer recurrence or death, alongside durable immune activity.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
2
The OncFive: Top Oncology Articles for the Week of 9/27/2026
3
AUA Releases Guideline Amendment for NMIBC
4
FLORA-2 Updates at World Lung: Biomarker Analysis, Safety Follow-Up, and ctDNA Monitoring
5